William Blair Initiates Coverage On Rhythm Pharmaceuticals with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform rating.
Stocks · News reference
Rhythm Pharmaceuticals Receives Health Canada Approval Of IMCIVREE For Additional Indication Of Weight Management In Adult And Pediatric Patients 4 Years Of Age And Older With Acquired Hypothalamic Obesity
IMCIVREE was first approved by Health Canada in 2023 for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome (BBS), or genetically confirmed biallelic
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $145
Reported Earlier, Rhythm Pharmaceuticals Launches IMCIVREE In Japan As First Approved Therapy For Acquired Hypothalamic Obesity, Backed By Phase 3 TRANSCEND Trial Showing 18.8% Placebo-Adjusted BMI Reduction
HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $130
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $105 to $130.